|
|
 |
|
Viewing report
|
|
|
|
Developments in Early-Stage Toxicity Prediction
Decision Resources, Inc., Oct 2008, Pages: 27
Drug toxicity is a major cause of costly late-stage development failures and devastating market withdrawals. To reduce these failures, researchers are developing novel toxicity prediction technologies that can be integrated into the early stages of drug development. Collaboration among regulatory agencies, pharmaceutical companies, and research institutions promises to advance this field.
Get the Answers You Need to Shape Your Strategy
- Companies are seeking alternatives to low-throughput, expensive animal studies for predicting drug toxicity. How advanced are these alternative technologies? How can these technologies be applied during drug discovery?
- The need for toxicity prediction tools provides opportunities for companies that can develop and exploit novel technologies. Which companies are developing and offering novel tools and/or services? What partnerships are these companies forming with Big Pharma? What types of technologies are commercially available?
- Drug manufacturers are concerned about regulatory acceptance of new toxicity assays and biomarkers. How are regulatory agencies addressing these concerns? What programs are available to industry to encourage working with regulatory agencies in the fi eld of toxicity prediction? What initiatives include participation by regulatory agencies?
- To develop reliable toxicity prediction tools, researchers require access to vast datasets of experimental and clinical information. How can researchers develop and access this information? How can public-private initiatives promote data-sharing among industry, government, and academia? What progress has been achieved by these initiatives?
Scope
- Drawbacks of traditional toxicology: traditional indicators; predictive reliability of animal models; throughput; cost.
- Emerging in vitro assays: microscale cell culture devices, toxicology microarrays; human embryonic stem cells.
- ‘Omics technologies: toxicogenomics; databases; commercial microarrays; proteomics, metabolomic profiling, voluntary genomic data submissions (VGDSs); voluntary exploratory data submissions (VXDSs).
- Novel predictive tools: Computational prediction tools; reference databases; novel animal models.
- Public-private projects and consortia: FDA; Critical Path Initiative; Predictive Safety Testing Consortium (PSTC); Development and Application of Biomarkers of Toxicity Technical Committee; Consortium for Metabonomic Toxicology; Environmental Protection Agency (EPA); National Toxicology Program; National Research Council; ToxCast.
- Company highlights: Companies involved in systems biology; bioinformatics; computational analysis; human embryonic stem cells; cell-based assays; toxicogenomics; reference databases; novel animal models.
Customers who bought this item also bought
Early Stage Drug Safety Strategies and Risk Management: Maximizing Opportunities Towards Achieving Clinical Success
Personalized Medicine - Scientific and Commercial Aspects
Preclinical Models: Innovative Solutions to Accelerate Drug Discovery and Development
What Is the Future Role of Predictive Safety Biomarkers in Drug Development?
Accelerating Lead Generation: Emerging Technologies and Strategies
Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
Applications of Stem Cells in Drug Discovery
Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs
Translational Medicine in Biopharmaceutical R&D: Enabling R&D Optimization and Early Detection of Potential Failures
Companion Biomarkers in Drug Development
|
|
|
|
